CD147 is an important adhesion molecule that plays a significant role in numerous pathological processes.[9] Many studies have reported CD147 overexpression in various carcinomas, with a significantly higher positivity rate and stronger expression intensity than that in normal tissues.[10] Our previous studies showed that Licartin ([131I] monoclonal antibody for CD147) was a safe and effective drug in treating patients with HCC and preventing post‐orthotopic liver transplantation tumor recurrence.[11, 12] However, radiological protection is required during the Licartin treatment. This evidence concerns the gene BSG and carcinoma.